Latest Research in Carcinoma of the Gastroesophageal Junction

Video

This video highlights the latest research in carcinoma of the gastroesophageal junction, including how using genetic information can help guide treatment.

In this video, Ian Chau, MD, of Royal Marsden Hospital in London, highlights the latest research in carcinoma of the gastroesophageal junction, including a look at immunotherapy in this disease, and how using genetic information can help guide treatment with chemotherapy.

In HER2-positive patients, where trastuzumab is standard in the first-line setting, studies are looking at how to optimize the use of this agent. Chau reviews the findings of two second-line studies that tested switching to a different type of chemotherapy after disease progression while continuing on with trastuzumab.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content